642 PATENT ABSTRACTS

pregnancy in cattle consisting of a glycoprotein obtained from a pregnant bovine animal which is characterized by having a specific immuno- logical reaction with a monoclonal antibody directed specifically against said glycoprotein wherein said monoclonal antibody is produced from hybridoma ATCC HB 8846.

4895833

L I V E R L A C T O G E N I C F A C T O R

L Stephen Frawley assigned to The Medical University of South Carolina

The present invention relates to liver lactogenic factor and to its isolation, purification and characterization. The liver lactogenic factor of the present inventiofi is useful to increase rail and/or casein production in lactating female mammals. The invention additionally pertains to a novel bioassay capable of identifying lac- togenic factors.

This invention teaches a method for determining the hormone cardiodilatin or active fragments thereof, well as antibodies thereto.

4897255

M E T A L R A D I O N U ( ~ L I D E L A B E L E D P R O T E I N S F O R

D I A G N O S I S A N D T H E R A P Y

Alan R Fritzberg, Sudhaka Kasina, Anan- thachari Srinivasan, Daniel S Wilbur assigned to NeoRx Corporation

Protein conjugated chelated metal radionuclides are provided for use in vivo. Intermediates are provided for preparing the polypeptide composi- tions efficiently.

4895864

A N T I B I O T I C TAN-950A, I T S P R O D U C T I O N A N D U S E

Takashi Iwasa, Shigetosh Tsubotani, Setsuo Harada, Kyoto, Japan assigned to Takeda Chemical Industries Ltd

As the novel antibiotic TAN-950A having the structural formula See Patent for Chemical Structure and salt thereof of the present inven- tion show antimicrobial action against fungi, they can be used in the therapeutics of fungal in- fections, in human and other animals etc. by oral, parenteral or external administration.

4895992

M E T H O D F O R D E T E R M I N I N G C A R D I O D I L A T I N A N D

F R A G M E N T S T H E R E O F A N D A N T I B O D I E S U S E F U L IN

D E T E R M I N A T I O N O F C A R D I O D I L A T I N A N D ITS

F R A G M E N T S

Wolf-Georg Forssmann, Heidelberg, Federal Republic Of Germany assigned to Organogen Medizinisch Molekularbiologische Forschungs- gesellschaft m b H

4897264

H U M A N G A M M A I N T E R F E R O N - S P E C I F I C R E C E P T O R P R O T E I N ,

A N T I B O D Y A G A I N S T S A I D P R O T E I N , M E T H O D S F O R

O B T A I N I N G S A I D P R O T E I N A N D S A I D A N T I B O D Y A N D

C O M P O S I T I O N S C O N T A I N I N G S A I D P R O T E I N A N D A N T I B O D Y

Daniel Novick, Patricia Orchansky, Dina Fischer, Menache Rubinstein, Rehovot, Israel assigned to Yeda Research and Development Co Ltd

Analysis of (125I). interferon gamma crnss- linked to its receptor on various human cells by SDS-PAGE revealed that there are at least three different types of human interferon gamma receptors. In WISH, HeLa, FSI 1 and the other tissue cells an Mr 90,000-105,000 receptor was found. In monocytes and in the myeloid cell line KG-1 an Mr 140,000 receptor was found while in Daudi lymphoblastoid cells an Mr 95,000- 115,000 receptor was found. The various recep- tors were isolated from these cells by extraction followed by affinity chromotography on an im- mobilized interferon gamma column. The resul- ting purified preparations retained their original affinity for interferon gamma and were used for immunizing mice and subsequent development of highly specific antibodies.